NCT06992258 2026-03-17
FRUITION
Criterium, Inc.
Phase 2 Recruiting
Clinical Trials
15 trialsNCT06562543 2026-02-27
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Takeda
Phase 4 Recruiting
NCT07235293 2026-02-03
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Medical
Phase 2 Recruiting
NCT07384377 2026-02-03
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT06195514 2026-01-30
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)
Takeda
No longer available
NCT05565417 2025-10-16
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
Phase 1/2 Active not recruiting
NCT06199973 2025-07-17
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Active not recruiting
NCT05848739 2025-05-11
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Sapience Therapeutics
Phase 1 Recruiting
NCT04322539 2025-04-04
FRESCO-2
Hutchmed
Phase 3 Completed
NCT03251378 2024-09-25
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
Phase 1 Completed
NCT05368805 2022-10-06
Fruquintinib DDI Study With P-gp and BCRP Substrates
Hutchmed
Phase 1 Completed
NCT03977090 2021-02-10
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
Genor Biopharma Co., Ltd.
Phase 1 Unknown
NCT02196688 2020-06-16
Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Hutchmed
Phase 2 Completed
NCT01975077 2020-02-17
A Phase Ib Study of Fruquintinib in 3rd Line mCRC
Hutchmed
Phase 1/2 Completed
NCT02314819 2020-02-17
FRESCO
Hutchmed
Phase 3 Completed